CardioInsight 3 - LBBB

Launched by CHINESE UNIVERSITY OF HONG KONG · Sep 22, 2022

Keywords

ClinConnect Summary

The CardioInsight 3 - LBBB trial is studying a new way to improve heart function in patients with heart failure who have a specific electrical conduction issue. This trial focuses on a treatment called Cardiac Resynchronization Therapy (CRT), which helps the heart beat more effectively. However, some patients do not respond well to the standard CRT method. In this study, doctors will place special leads in the heart to see if a different pacing approach can help these patients. By using advanced technology to monitor the heart's response, the trial aims to find the best way to enhance heart function and correct the electrical issue.

To participate in this trial, individuals must be at least 18 years old and meet specific criteria for CRT therapy. They should have been on stable heart medication for at least three months and must be able to give informed consent. Pregnant individuals and those already involved in another study are not eligible. Participants can expect to undergo a procedure where the new pacing leads are implanted and monitored to assess their heart's performance. This study is actively recruiting participants, and it could potentially lead to better treatment options for those struggling with heart failure and conduction problems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (aged 18 or above) of both sexes
• • Candidate for CRT therapy according to international guidelines.7
• • Informed consent by the patient
• • Already received stable dose of guideline directed medical therapy for at least 3 months
• Exclusion Criteria:
• • Pregnant
• • Participating in another study